EUCTR2013-001442-34-SE进行中（未招募）不适用
A SINGLE-DOSE, RANDOMIZED, TWO-PERIOD, CROSSOVER STUDY TO ASSESS BIOEQUIVALENCE BETWEEN TWO IBUPROFEN 200 MG TABLET FORMULATIONS, IN HEALTHY ADULTS.
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- McNeil AB
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Healthy male or female volunteers subjects between the ages of 18 and 50 years, inclusive. Health is defined as the absence of clinically relevant abnormalities as judged by the investigator, based on a detailed medical history, a physical examination, including blood pressure and pulse rate measurements, 12-lead electrocardiogram, as well as clinical laboratory tests. The responsible investigator may request additional investigations or analyses if necessary.
- •2. Non- or ex-tobacco user, being defined as someone who completely stopped smoking or using any form of tobacco or nicotine for at least 12 months before screening visit of this study.
- •3. For females: Postmenopausal state (absence of menstrual discharge for at least two years and a follicle stimulating hormone (FSH) serum level exceeding 30 IU/L) or premenopausal/perimenopausal state with an effective means of contraception (oral, injected, implanted, transdermal, hormonal contraceptives, vaginal contraceptive ring, intrauterine device, or status after operative sterilization), single male partner who has had a vasectomy, or declared absence of sexual contact, with a male partner, during the study.
- •Males: No pregnant spouse or partner at screening and willingness to protect potential spouse or partner from becoming pregnant during the study.
- •4. Body Mass Index (BMI) = 18.5 and = 30.0 kg/m2.
- •5. A personally signed and dated informed consent document, indicating that the subject has been informed of all pertinent aspects of the study.
- •6. Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures specified in the protocol.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 30
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Use of medications other than contraceptives or occasional use of paracetamol or NSAIDs.
- •2. Use of NSAIDs (or any other product containing NSAIDs) within 7 days before the first treatment visit and throughout the study.
- •3. History of significant allergy or hypersensivity (e.g. asthma, angioedema) to ibuprofen, ASA, other NSAIDs or any related products (including excipients of the formulations).
- •4. Females: Pregnancy and/or breast-feeding.
- •5. History of peptic ulcer or gastrointestinal bleeding.
- •6. Treatment with an investigational drug within 3 months preceding the first dose of study treatment.
- •7. Preplanned surgical procedures during the study period, if this may interfere with the conduct of the study.
- •8. History of regular alcohol consumption in the 6 months before screening, exceeding weekly limits of 2 L of wine or 5 L of beer or 0.6 L of spirits for females, and 3 L of wine or 7.5 L of beer or 0.9 L of spirits for males. The investigator may lower these limits if a subject consumes different types of alcoholic beverages.
- •9. Donation or loss of blood within 3 months prior to the first treatment visit if the estimated lost blood volume equaled or exceeded 450 mL.
- •10. Relationship to persons involved directly in the conduct of the study (i.e., principal investigator, sub-investigators, study coordinators, other study personnel, employees or contractors of the sponsor or Johnson & Johnson subsidiaries, and the family of each).
研究者
相似试验
进行中（未招募）
不适用
A single dose, randomized, 2-period crossover study in patients with hemophilia A to evaluate the pharmacokinetics of ReFactoO' [B-domain deleted recombinant human factor VIII (BDDrFVIII)] and AdvateO' [a full-length recombinant factor VIII (FLrFVIII)]Prevention and treatment of bleedings in patients with haemophilia AMedDRA version: 14.1Level: PTClassification code 10056493Term: Haemophilia A without inhibitorsSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2004-003727-12-ITWYETH LEDERLE30
进行中（未招募）
1 期
A single-dose, randomized, two-period, two-sequence, crossover comparative bioavailability study on formulations containing ramipril, amlodipine and indapamide in combination product versus Triatec® 10 mg capsules (Sanofi - Produtos Farmacêuticos, Lda., Portugal), containing ramipril, Norvasc® 10 mg, tablets (Upjohn EESV, the Netherlands), containing amlodipine and Natrilix® 2.5 mg film-coated tablets (Les Laboratoires Servier, France), containing indapamide co-administered together as reference in healthy male and female volunteers under fasting conditions.hypertensionCTIS2024-514456-32-00Zaklady Farmaceutyczne Polpharma S.A.72
已完成
1 期
Comparative Study of 3 Tocilizumab Products in Normal Healthy VolunteeersCTRI/2022/01/039850Dr Reddys Laboratories Ltd127
已完成
1 期
A single dose phase 1 study to evaluate safety and Pharmacokinetics of three tocilizumab products in normal healthy volunteersRheumatoid arthritis (RA)Giant Cell Arteritis (GCA)Inflammatory and Immune System - Autoimmune diseasesACTRN12621000663853Dr. Reddy’s Laboratories Ltd., Biologics300
撤回
1 期
Comparative bioavailability assessment between 1 x 60 mg R-192 tablet and 1 x 60 mg R-107 tablet administered orally in healthy participants under fasting conditions.DepressionMental Health - DepressionMental Health - AnxietyAnxietyACTRN12622000446763Zenith Technology Corporation Limited14